Baijin Life Science Holdings (HKG:1466) is poised to raise HK$31.3 million in net proceeds from issuing 65.3 million shares to 20 subscribers.
The subscription price is HK$0.48 per share, according to a Tuesday filing with the Hong Kong bourse.
The funds raised will be utilized for the company's general working capital.
Completion is subject to regulatory approvals, and the company has applied for listing permission from the Hong Kong Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.